

Contents

List of Contributors	XIX
Preface	XXIII
A Personal Foreword	XXV

1	Introduction: The Why and How of Drug Bioavailability Research	1
	<i>Han van de Waterbeemd and Bernard Testa</i>	
1.1	Defining Bioavailability	1
1.1.1	The Biological Context	1
1.1.2	A Pharmacokinetic Overview	3
1.1.3	Specific Issues	3
1.2	Presentation and Layout of the Book	4
	References	6

Part One Physicochemical Aspects of Drug Dissolution and Solubility 7

2	Aqueous Solubility in Drug Discovery Chemistry, DMPK, and Biological Assays	9
	<i>Nicola Colclough, Linette Ruston, and Kin Tam</i>	
2.1	Introduction	10
2.1.1	Definition of Aqueous Solubility	11
2.1.2	Aqueous Solubility in Different Phases of Drug Discovery	12
2.2	Aqueous Solubility in Hit Identification	12
2.2.1	Aqueous Solubility from DMSO Solutions	13
2.2.1.1	Turbidimetric Methods	14
2.2.1.2	UV Absorption Methods	15
2.2.1.3	Alternative Detection Methodology	17
2.2.1.4	Application of DMSO-Based Solubility Assays	18

2.3	Aqueous Solubility in Lead Identification and Lead Optimization	18
2.3.1	Dried-Down Solution Methods	20
2.3.2	Solubility from Solid	21
2.3.3	Thermodynamic Solubility Assays with Solid-State Characterization	22
2.3.4	Solubility by Potentiometry	24
2.3.5	Application of Thermodynamic Solubility Data in LI and LO	26
2.4	Conclusions	28
	References	28
3	Gastrointestinal Dissolution and Absorption of Class II Drugs	33
	<i>Arik S. Dahan and Gordon L. Amidon</i>	
3.1	Introduction	33
3.2	Drug Absorption and the BCS	34
3.3	Class II Drugs	36
3.4	GI Physiological Variables Affecting Class II Drug Dissolution	38
3.4.1	Bile Salts	38
3.4.2	GI pH	39
3.4.3	GI Transit	39
3.4.4	Drug Particle Size	40
3.4.5	Volume Available for Dissolution	41
3.5	<i>In Vitro</i> Dissolution Tests for Class II Drugs	41
3.5.1	Biorelevant Media	41
3.5.2	Dynamic Lipolysis Model	42
3.6	BCS-Based FDA Guidelines: Implications for Class II Drugs	43
3.6.1	Potential of Redefining BCS Solubility Class Boundary	43
3.6.2	Biowaiver Extension Potential for Class II Drugs	44
3.7	Conclusions	45
	References	45
4	<i>In Silico</i> Prediction of Solubility	53
	<i>Andrew M. Davis and Pierre Bruneau</i>	
4.1	Introduction	54
4.2	What Solubility Measures to Model?	54
4.3	Is the Data Set Suitable for Modeling?	56
4.4	Descriptors and Modeling Methods for Developing Solubility Models	58
4.5	Comparing Literature Solubility Models	59
4.6	What Is the Influence of the Domain of Applicability?	63
4.7	Can We Tell when Good Predictions Are Made?	65
4.8	Conclusions	65
	References	66

Part Two Physicochemical and Biological Studies of Membrane Permeability and Oral Absorption 69

5 Physicochemical Approaches to Drug Absorption 71

Han van de Waterbeemd

- 5.1 Introduction 73
- 5.2 Physicochemical Properties and Pharmacokinetics 74
 - 5.2.1 DMPK 74
 - 5.2.2 Lipophilicity, Permeability, and Absorption 74
 - 5.2.3 Estimation of Volume of Distribution from Physical Chemistry 76
 - 5.2.4 Plasma Protein Binding and Physicochemical Properties 76
- 5.3 Dissolution and Solubility 76
 - 5.3.1 Calculated Solubility 78
- 5.4 Ionization (pK_a) 78
 - 5.4.1 Calculated pK_a 79
- 5.5 Molecular Size and Shape 79
 - 5.5.1 Calculated Size Descriptors 79
- 5.6 Hydrogen Bonding 80
 - 5.6.1 Calculated Hydrogen-Bonding Descriptors 80
- 5.7 Lipophilicity 81
 - 5.7.1 $\log P$ and $\log D$ 81
 - 5.7.2 Calculated $\log P$ and $\log D$ 83
- 5.8 Permeability 84
 - 5.8.1 Artificial Membranes and PAMPA 84
 - 5.8.1.1 *In Silico* PAMPA 85
 - 5.8.2 IAM, ILC, MEKC, and BMC 85
 - 5.8.3 Liposome Partitioning 86
 - 5.8.4 Biosensors 86
- 5.9 Amphiphilicity 86
- 5.10 Drug-Like Properties 87
- 5.11 Computation Versus Measurement of Physicochemical Properties 88
 - 5.11.1 QSAR Modeling 88
 - 5.11.2 *In Combo*: Using the Best of Two Worlds 89
- 5.12 Outlook 89
- References 89

6 High-Throughput Measurement of Physicochemical Properties 101

Barbara P. Mason

- 6.1 Introduction 102
- 6.2 Positioning of Physicochemical Screening in Drug Discovery 102
- 6.3 “Fit for Purpose” Versus “Gold Standard” 103
- 6.4 Solubility 104
 - 6.4.1 “Thermodynamic” Versus “Kinetic” 104
 - 6.4.2 Methods of Measuring High-Throughput Solubility 106

6.4.3	Supernatant Concentration	106
6.4.4	Measuring Solubility Across a pH Range	107
6.4.5	Supernatant Concentration Methods from Solid Material	109
6.4.6	Precipitate Detection	109
6.4.7	Other Methods of Measuring Solubility	110
6.5	Dissociation Constants, pK_a	110
6.5.1	Measuring pK_a	111
6.5.2	pK_a Measurements in Cosolvent Mixtures	112
6.5.3	pK_a Measurements based on Separation	113
6.6	Lipophilicity	115
6.6.1	$\log P$ Versus $\log D_{pH}$	115
6.6.2	Measuring Lipophilicity	116
6.6.3	High-Throughput $\log D_{7.4}$ Measurements	117
6.6.4	High-Throughput $\log D_{7.4}$ Versus Shake-Flask $\log D_{7.4}$	117
6.6.5	Alternative Methods for Determining High-Throughput $\log D_{pH}$	118
6.7	Permeability	119
6.7.1	Permeability and Lipophilicity	121
6.7.2	Cell-Based Assays	121
6.7.3	Noncell-Based Assays: Chromatographic Methods	122
6.7.4	Noncell-Based Assays: Parallel Artificial Membrane Permeability Assay	122
6.7.4.1	Membrane Composition	123
6.7.4.2	Suggestions for PAMPA	123
6.7.4.3	Considerations in the Calculation of Permeability from PAMPA Data	124
6.7.5	Sink Conditions	125
6.7.6	Unstirred Water Layer	126
6.7.7	Surface Properties for the Determination of Permeability	126
6.8	Data Interpretation, Presentation, and Storage	126
6.9	Conclusions	127
	References	127
7	An Overview of Caco-2 and Alternatives for Prediction of Intestinal Drug Transport and Absorption	133
	<i>Anna-Lena Ungell and Per Artursson</i>	
7.1	Introduction	134
7.2	Cell Cultures for Assessment of Intestinal Permeability	134
7.2.1	Caco-2	135
7.2.2	MDCK Cells	136
7.2.3	2/4/A1 Cells	137
7.2.4	Other Cell Lines	139
7.3	Correlation to Fraction of Oral Dose Absorbed	140
7.4	Cell Culture and Transport Experiments	141
7.4.1	Quality Control and Standardization	143

7.4.2	Optimizing Experimental Conditions: pH	144
7.4.3	Optimizing Experimental Conditions: Concentration Dependence	144
7.4.4	Optimizing Experimental Conditions: Solubility and BSA	145
7.5	Active Transport Studies in Caco-2 Cells	145
7.6	Metabolism Studies using Caco-2 Cells	146
7.7	Conclusions	147
	References	148

8 Use of Animals for the Determination of Absorption and Bioavailability 161

Chris Logan

8.1	Introduction	162
8.1.1	ADME/PK in Drug Discovery	162
8.1.2	The Need for Prediction	163
8.2	Consideration of Absorption and Bioavailability	163
8.3	Choice of Animal Species	167
8.4	Methods	168
8.4.1	Radiolabels	169
8.4.2	<i>Ex Vivo</i> Methods for Absorption	169
8.4.2.1	Static Method	169
8.4.2.2	Perfusion Methods	170
8.4.3	<i>In Vivo</i> Methods	170
8.5	<i>In Vivo</i> Methods for Determining Bioavailability	171
8.5.1	Cassette Dosing	171
8.5.2	Semisimultaneous Dosing	172
8.5.3	Hepatic Portal Vein Cannulation	173
8.6	Inhalation	173
8.7	Relevance of Animal Models	174
8.7.1	Models for Prediction of Absorption	174
8.7.2	Models for Prediction of Volume	175
8.8	Prediction of Dose in Man	176
8.8.1	Allometry	176
8.8.2	Physiologically Based Pharmacokinetics	176
8.8.3	Prediction of Human Dose	177
8.9	Conclusions	179
	References	179

9 *In Vivo* Permeability Studies in the Gastrointestinal Tract of Humans 185

Niclas Petri and Hans Lennernäs

9.1	Introduction	185
9.2	Definitions of Intestinal Absorption, Presystemic Metabolism, and Absolute Bioavailability	188
9.3	Methodological Aspects of <i>In Vitro</i> Intestinal Perfusion Techniques	190

9.4	Paracellular Passive Diffusion	193
9.5	Transcellular Passive Diffusion	196
9.6	Carrier-Mediated Intestinal Absorption	199
9.7	Jejunal Transport and Metabolism	202
9.8	Regional Differences in Transport and Metabolism of Drugs	208
9.9	Conclusions	209
	References	210

Part Three Role of Transporters and Metabolism in Oral Absorption 221

10	Transporters in the Gastrointestinal Tract	223
	<i>Pascale Anderle and Carsten U. Nielsen</i>	
10.1	Introduction	223
10.2	Active Transport Along the Intestine and Influence on Drug Absorption	228
10.2.1	Peptide Transporters	232
10.2.2	Nucleoside Transporters	233
10.2.3	Amino Acid Transporters	234
10.2.4	Monosaccharide Transporters	234
10.2.5	Organic Cation Transporters	235
10.2.6	Organic Anion Transporters	235
10.2.7	Monocarboxylate Transporters	235
10.2.8	ABC Transporters	235
10.2.9	Bile Acid Transporters	237
10.3	Transporters and Genomics	237
10.3.1	Introduction to Genomics Technologies	237
10.3.2	Gene Expression Profiling Along the Intestine and in Caco-2 Cells	238
10.3.2.1	Profiling of the Intestinal Mucosa	238
10.3.2.2	Profiling of Caco-2 Cells	240
10.3.3	Intestinal Transporters and the Influence of Genotypes	242
10.4	Structural Requirements for Targeting Absorptive Intestinal Transporters	245
10.4.1	Strategies for Increasing Drug Absorption Targeting Transporters	245
10.4.2	Changing the Substrate: SAR Established for PEPT1	247
10.4.3	Methods for Investigating Affinity and Translocation	248
10.4.4	Quantitative Structure–Activity Relations for Binding of Drug to Transporters	249
10.5	Transporters and Diseased States of the Intestine	251
10.5.1	Intestinal Diseases	251
10.5.2	Basic Mechanisms in Cancer and Specifically in Colon Carcinogenesis	252
10.5.2.1	Basic Mechanisms	252

10.5.2.2	Colon Cancer	253
10.5.3	Transporters and Colon Cancer	253
10.5.3.1	Transporters as Tumor Suppressor Genes	255
10.5.3.2	Role of Transporters in the Tumor–Stroma Interaction	255
10.5.3.3	Role of Transporters in Intestinal Stem Cells	258
10.5.4	Role of PEPT1 in Inflammatory Bowel Disease	259
10.6	Summary and Outlook	260
	References	261
11	Hepatic Transport	277
	<i>Kazuya Maeda, Hiroshi Suzuki, and Yuichi Sugiyama</i>	
11.1	Introduction	278
11.2	Hepatic Uptake	278
11.2.1	NTCP (<i>SLC10A1</i>)	279
11.2.2	OATP (<i>SLCO</i>) Family Transporters	279
11.2.3	OAT (<i>SLC22</i>) Family Transporters	281
11.2.4	OCT (<i>SLC22</i>) Family Transporters	284
11.3	Biliary Excretion	284
11.3.1	MDR1 (P-glycoprotein; <i>ABCB1</i>)	287
11.3.2	MRP2 (<i>ABCC2</i>)	287
11.3.3	BCRP (<i>ABCG2</i>)	289
11.3.4	BSEP (<i>ABCB11</i>)	290
11.3.5	MATE1 (<i>SLC47A1</i>)	290
11.4	Sinusoidal Efflux	290
11.4.1	MRP3 (<i>ABCC3</i>)	291
11.4.2	MRP4 (<i>ABCC4</i>)	291
11.4.3	Other Transporters	293
11.5	Prediction of Hepatobiliary Transport of Substrates from <i>In Vitro</i> Data	294
11.5.1	Prediction of Hepatic Uptake Process from <i>In Vitro</i> Data	294
11.5.2	Prediction of the Contribution of Each Transporter to the Overall Hepatic Uptake	295
11.5.3	Prediction of Hepatic Efflux Process from <i>In Vitro</i> Data	298
11.5.4	Utilization of Double (Multiple) Transfected Cells for the Characterization of Hepatobiliary Transport	299
11.6	Genetic Polymorphism of Transporters and Its Clinical Relevance	301
11.7	Transporter-Mediated Drug–Drug Interactions	305
11.7.1	Effect of Drugs on the Activity of Uptake Transporters Located on the Sinusoidal Membrane	305
11.7.2	Effect of Drugs on the Activity of Efflux Transporters Located on the Bile Canalicular Membrane	308
11.7.3	Prediction of Drug–Drug Interaction from <i>In Vitro</i> Data	309
11.8	Concluding Remarks	309
	References	311

12	The Importance of Gut Wall Metabolism in Determining Drug Bioavailability	333
	<i>Christopher Kohl</i>	
12.1	Introduction	334
12.2	Physiology of the Intestinal Mucosa	334
12.3	Drug-Metabolizing Enzymes in the Human Mucosa	336
12.3.1	Cytochrome P450	336
12.3.2	Glucuronyltransferase	337
12.3.3	Sulfotransferase	337
12.3.4	Other Enzymes	337
12.4	Oral Bioavailability	341
12.4.1	<i>In Vivo</i> Approaches to Differentiate Between Intestinal and Hepatic First-Pass Metabolism	342
12.4.2	<i>In Vitro</i> Approaches to Estimate Intestinal Metabolism	344
12.4.3	Computational Approaches to Estimate and to Predict Human Intestinal Metabolism	345
12.5	Clinical Relevance of Gut Wall First-Pass Metabolism	347
	References	347
13	Modified Cell Lines	359
	<i>Guangqing Xiao and Charles L. Crespi</i>	
13.1	Introduction	359
13.2	Cell/Vector Systems	360
13.3	Expression of Individual Metabolic Enzymes	363
13.4	Expression of Transporters	365
13.4.1	Efflux Transporters	365
13.4.2	Uptake Transporters	367
13.5	Summary and Future Perspectives	368
	References	368
Part Four	Computational Approaches to Drug Absorption and Bioavailability	373
14	Calculated Molecular Properties and Multivariate Statistical Analysis	375
	<i>Ulf Norinder</i>	
14.1	Introduction	377
14.2	Calculated Molecular Descriptors	377
14.2.1	2D-Based Molecular Descriptors	377
14.2.1.1	Constitutional Descriptors	378
14.2.1.2	Fragment- and Functional Group-Based Descriptors	378
14.2.1.3	Topological Descriptors	379
14.2.2	3D Descriptors	381
14.2.2.1	WHIM Descriptors	381
14.2.2.2	Jurs Descriptors	382
14.2.2.3	VolSurf and Almond Descriptors	383

14.2.2.4	Pharmacophore Fingerprints	384
14.2.3	Property-Based Descriptors	385
14.2.3.1	$\log P$	385
14.2.3.2	HYBOT Descriptors	386
14.2.3.3	Abraham Descriptors	386
14.2.3.4	Polar Surface Area	386
14.3	Statistical Methods	387
14.3.1	Linear and Nonlinear Methods	388
14.3.1.1	Multiple Linear Regression	388
14.3.1.2	Partial Least Squares	389
14.3.1.3	Artificial Neural Networks	390
14.3.1.4	Bayesian Neural Networks	390
14.3.1.5	Support Vector Machines	390
14.3.1.6	k -Nearest Neighbor Modeling	392
14.3.1.7	Linear Discriminant Analysis	392
14.3.2	Partitioning Methods	393
14.3.2.1	Traditional Rule-Based Methods	393
14.3.2.2	Rule-Based Methods Using Genetic Programming	394
14.3.3	Consensus and Ensemble Methods	395
14.4	Applicability Domain	396
14.5	Training and Test Set Selection and Model Validation	398
14.5.1	Training and Test Set Selection	398
14.5.2	Model Validation	399
14.6	Future Outlook	400
	References	401
15	Computational Absorption Prediction	409
	<i>Christel A.S. Bergström, Markus Haeberlein, and Ulf Norinder</i>	
15.1	Introduction	410
15.2	Descriptors Influencing Absorption	410
15.2.1	Solubility	411
15.2.2	Membrane Permeability	412
15.3	Computational Models of Oral Absorption	413
15.3.1	Quantitative Predictions of Oral Absorption	413
15.3.1.1	Responses: Evaluations of Measurement of Fraction Absorbed	417
15.3.1.2	Model Development: Data sets, Descriptors, Technologies, and Applicability	419
15.3.2	Qualitative Predictions of Oral Absorption	420
15.3.2.1	Model Development: Data sets, Descriptors, Technologies, and Applicability	420
15.3.2.2	An Example Using Genetic Programming-Based Rule Extraction	426
15.3.3	Repeated Use of Data Sets	427
15.4	Software for Absorption Prediction	427
15.5	Future Outlook	428
	References	429

16	<i>In Silico</i> Prediction of Human Bioavailability	433
	<i>David J. Livingstone and Han van de Waterbeemd</i>	
16.1	Introduction	434
16.2	Concepts of Pharmacokinetics and Role of Oral Bioavailability	437
16.3	<i>In Silico</i> QSAR Models of Oral Bioavailability	438
16.3.1	Prediction of Human Bioavailability	438
16.3.2	Prediction of Animal Bioavailability	441
16.4	Prediction of the Components of Bioavailability	441
16.5	Using Physiological Modeling to Predict Oral Bioavailability	443
16.6	Conclusions	445
	References	446
17	Simulations of Absorption, Metabolism, and Bioavailability	453
	<i>Michael B. Bolger, Robert Fraczekiewicz, and Viera Lukacova</i>	
17.1	Introduction	454
17.2	Background	454
17.3	Use of Rule-Based Computational Alerts in Early Discovery	456
17.3.1	Simple Rules for Drug Absorption (Druggability)	456
17.3.2	Complex Rules That Include Toxicity	473
17.4	Mechanistic Simulation (ACAT Models) in Early Discovery	474
17.4.1	Automatic Scaling of k'_a as a Function of P_{eff} , pH, log D, and GI Surface Area	477
17.4.2	Mechanistic Corrections for Active Transport and Efflux	478
17.4.3	PBPK and <i>In Silico</i> Estimation of Distribution	481
17.5	Mechanistic Simulation of Bioavailability (Drug Development)	481
17.5.1	Approaches to <i>In Silico</i> Estimation of Metabolism	484
17.6	Regulatory Aspects of Modeling and Simulation (FDA Critical Path Initiative)	484
17.7	Conclusions	485
	References	485
18	Toward Understanding P-Glycoprotein Structure–Activity Relationships	497
	<i>Anna Seelig</i>	
18.1	Introduction	498
18.1.1	Similarity Between P-gp and Other ABC Transporters	498
18.1.2	Why P-gp Is Special	500
18.2	Measurement of P-gp Function	500
18.2.1	P-gp ATPase Activity Assay	500
18.2.1.1	Quantification of Substrate–Transporter Interactions	503
18.2.1.2	Relationship between Substrate–Transporter Affinity and Rate of Transport	504
18.2.2	Transport Assays	506

18.2.3	Competition Assays	508
18.3	Predictive <i>In Silico</i> Models	508
18.3.1	Introduction to Structure–Activity Relationship	509
18.3.2	3D-QSAR Pharmacophore Models	509
18.3.3	Linear Discriminant Models	510
18.3.4	Modular Binding Approach	511
18.3.5	Rule-Based Approaches	512
18.4	Discussion	513
18.4.1	Prediction of Substrate-P-gp Interactions	513
18.4.2	Prediction of ATPase Activity or Intrinsic Transport	513
18.4.3	Prediction of Transport (i.e., Apparent Transport)	513
18.4.4	Prediction of Competition	514
18.4.5	Conclusions	514
	References	514

Part Five Drug Development Issues 521

19 Application of the Biopharmaceutics Classification System Now and in the Future 523

Bertil Abrahamsson and Hans Lennernäs

19.1	Introduction	524
19.2	Definition of Absorption and Bioavailability of Drugs Following Oral Administration	527
19.3	Dissolution and Solubility	528
19.4	The Effective Intestinal Permeability (P_{eff})	535
19.5	Luminal Degradation and Binding	539
19.6	The Biopharmaceutics Classification System	541
19.6.1	Regulatory Aspects	541
19.6.1.1	Present Situation	541
19.6.1.2	Potential Future Extensions	543
19.6.2	Drug Development Aspects	543
19.6.2.1	Selection of Candidate Drugs	544
19.6.2.2	Choice of Formulation Principle	545
19.6.2.3	<i>In Vitro/In Vivo</i> Correlation	547
19.6.2.4	Food–Drug Interactions	549
19.6.2.5	Quality by Design	552
19.7	Conclusions	552
	References	553

20 Prodrugs 559

Bernard Testa

20.1	Introduction	559
20.2	Why Prodrugs?	560
20.2.1	Pharmaceutical Objectives	560

20.2.2	Pharmacokinetic Objectives	561
20.2.3	Pharmacodynamic Objectives	564
20.3	How Prodrugs?	565
20.3.1	Types of Prodrugs	565
20.3.2	Hurdles in Prodrug Research	567
20.4	Conclusions	568
	References	568

21 **Modern Delivery Strategies: Physiological Considerations for Orally Administered Medications** 571

Clive G. Wilson and Werner Weitschies

21.1	Introduction	571
21.2	The Targets	572
21.3	The Upper GI Tract: Mouth and Esophagus	573
21.3.1	Swallowing the Bitter Pill...	575
21.4	Mid-GI Tract: Stomach and Intestine	576
21.4.1	Gastric Inhomogeneity	576
21.4.2	Gastric Emptying	579
21.4.3	Small Intestinal Transit Patterns	581
21.4.4	Modulation of Transit to Prolong the Absorption Phase	582
21.4.5	Absorption Enhancement	582
21.5	The Lower GI Tract: The Colon	583
21.5.1	Colonic Transit	584
21.5.2	Time of Dosing	585
21.5.3	Modulating Colonic Water	586
21.6	Pathophysiological Effects on Transit	587
21.7	Pathophysiological Effects on Permeability	589
21.8	pH	589
21.9	Conclusions	590
	References	590

22 **Nanotechnology for Improved Drug Bioavailability** 597

Marjo Yliperttula and Arto Urtti

22.1	Introduction	597
22.2	Nanotechnological Systems in Drug Delivery	599
22.2.1	Classification of the Technologies	599
22.2.1.1	Nanocrystals	599
22.2.1.2	Self-Assembling Nanoparticulates	600
22.2.1.3	Processed Nanoparticulates	601
22.2.1.4	Single-Molecule-Based Nanocarriers	601
22.2.2	Pharmaceutical Properties of Nanotechnological Formulations	601
22.2.2.1	Drug-Loading Capacity	601
22.2.2.2	Processing	602
22.2.2.3	Biological Stability	602
22.3	Delivery via Nanotechnologies	603

22.3.1	Delivery Aspects at Cellular Level	603
22.3.2	Nanosystems for Improved Oral Drug Bioavailability	606
22.3.3	Nanosystems for Improved Local Drug Bioavailability	606
22.4	Key Issues and Future Prospects	608
	References	609

Index	613
--------------	------------

